Skip to main content
. Author manuscript; available in PMC: 2014 Mar 14.
Published in final edited form as: Oncogene. 2011 Jun 6;31(1):13–26. doi: 10.1038/onc.2011.211

Figure 7. Daxx levels have reverse correlation with taxane chemotherapy response in breast cancer patients.

Figure 7

Twenty-two women with breast cancer who were treated with standard taxane and anthracycline based neoadjuvant chemotherapy were classified as either responders (up to 75% reduction of tumor size; 10 patients) or non-responders (less than 75% reduction of tumor size; 12 patients). Daxx score was calculated based on the Daxx IHC staining intensity multiplied by the percent of staining cells. Comparison of pretreatment samples between the responders and non-responders was performed using an independent sample t test. Responders to therapy had a higher mean Daxx score compared to non-responders (p=0.06).